Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Show more
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a...
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1334 | -14.5157780196 | 0.919 | 0.969999 | 0.61 | 67692 | 0.78473455 | CS |
| 4 | -0.2944 | -27.2592592593 | 1.08 | 1.125 | 0.61 | 110069 | 0.94770067 | CS |
| 12 | -0.1744 | -18.1666666667 | 0.96 | 1.44 | 0.61 | 1120446 | 1.16947139 | CS |
| 26 | -1.2144 | -60.72 | 2 | 4.55 | 0.61 | 1195221 | 2.05359782 | CS |
| 52 | -9.3144 | -92.2217821782 | 10.1 | 12.36598 | 0.61 | 996178 | 3.01475646 | CS |
| 156 | -87.6144 | -99.1113122172 | 88.4 | 105.6 | 0.61 | 612421 | 9.78778403 | CS |
| 260 | -154.4144 | -99.493814433 | 155.2 | 486.8 | 0.61 | 634846 | 70.88852777 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
